Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

32:04
 
Share
 

Manage episode 469983906 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.
  continue reading

372 episodes

Artwork
iconShare
 
Manage episode 469983906 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.
  continue reading

372 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play